Patents
Sitemap › C07 - Organic chemistry › C07K - Peptides › C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526)
10/2005
10/13/2005WO2004072253A3 Human excitatory amino acid transporter-2 gene promoter and uses thereof
10/13/2005WO2004067570A3 Prostate cancer diagnosis and treatment
10/13/2005WO2004062578A3 Methods for reducing mortality associated with acute myocardial infarction
10/13/2005WO2003099779A3 Hemipteran muscarinic receptor
10/13/2005WO2003088919A3 Compositions and methods for diagnostics and therapeutics for hydrocephalus
10/13/2005WO2003069980A3 Precise breeding
10/13/2005WO2003068954A8 Microorganism for genetic therapeutic treatment of proliferative diseases
10/13/2005WO2003006154A3 Protein design automation for designing protein libraries with altered immunogenicity
10/13/2005WO2002014467A9 Cng2b: a putative human cyclic nucleotide-gated ion channel
10/13/2005US20050229273 Enhancing the level of expression of a selected heterologous protein in seeds of transgenic plants
10/13/2005US20050229272 Compositions and methods for gene silencing
10/13/2005US20050229271 Compositions and methods for altering amino acid content of proteins
10/13/2005US20050229270 Using the polycomb proteins fertilization independent endosperm (FIE) and medea (MEA) for controlling activities of non-endosperm tissues such as floral meristem
10/13/2005US20050229268 Plant carbon catabolite repression proteins
10/13/2005US20050229267 Precise breeding
10/13/2005US20050229264 Recombinant gelatins
10/13/2005US20050229263 Transgenesis by sperm-mediated gene transfer
10/13/2005US20050229261 Method for producing biologically active human factor VIII in the milk of transgenic animals driven by mammary-specific expression cassettes
10/13/2005US20050228171 Purification method
10/13/2005US20050228170 B7-like molecules and uses thereof
10/13/2005US20050228169 Polypeptide binding to human syntaxin 1a
10/13/2005US20050227924 Peyer's patch and/or M-cell targeting ligands
10/13/2005US20050227920 Methods for production of recombinant vascular endothelial cell growth inhibitor
10/13/2005US20050227917 Gene products differentially expressed in cancerous cells and their methods of use II
10/13/2005US20050227916 Administering carrier molecule such as albumin conjugated to mannose-6-phosphate; particularly targeting Hepatic Stellate Cells (HSC); glomeruloscherosis, interstitial fibrosis, lung fibrosis, atherosclerosis, Crohn's disease, colitis ulcerosa, glomerulonephritis and sepsis; diagnosis
10/13/2005US20050227913 Reducing the immunogenicity of a therapeutic peptide, polypeptide or protein (Factor VIII) by complexing it with a serine compound, phosphatidylcholine, phosphatidylethanolamine, phosphatidic acid ore a phospholipid containing them; may be used to treat Hemophilia
10/13/2005US20050227912 Hemoglobin composed 2 polypeptides, each having a normal human hemoglobin alpha chain amino acid sequence, and 2 polypeptides, each having a normal normal bovine hemoglobin beta chain amino acid sequence; at least one polypeptide has a mutation that introduces a polymerization site; nucleic acid
10/13/2005US20050227911 Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules
10/13/2005US20050227345 Quorum sensing signaling in bacteria
10/13/2005US20050227343 Novel human protease inhibitor proteins and polynucleotides encoding the same
10/13/2005US20050227342 Expression vector comprising nucleotide sequences coding membrane protein for use in diagnosis, prevention and treatment of cell proliferative, inflammatory, neurodegenerative and infectious disorders
10/13/2005US20050227330 growth hormone supergene family; prolongs circulating half-lives of protein therapeutics in the body so proteins do not have to be injected frequently; adding cysteine residues to non-essential regions using site-directed mutagenesis; covalently coupling a cysteine-reactive polymer via the added cysteine
10/13/2005US20050227329 Recombinant fibroblast growth factor analogs
10/13/2005US20050227328 Secreted and transmembrane polypeptides and nucleic acids encoding the same
10/13/2005US20050227326 Obtaining vector comprising a modified PLAC4 having a mutation in one or more Pribnow box-like sequences into which gene encoding target protein has been inserted; reduction in gene expression when vector is cloned in bacteria; transformation
10/13/2005US20050227325 Recombinant polynucleotide
10/13/2005US20050227322 Recombinant prion-like genes and proteins and materials and methods comprising the same
10/13/2005US20050227321 Producing antimicrobial peptides (AMPs) by using microbes; not necessary to offset the positive charges of multiple copies of AMPs in multimeric constructs; enables the use of a wider range of multimers and carrier peptides
10/13/2005US20050227314 selectively splitting the polypeptide at a Cys-His site, by hydrolysis in presence of a palladium promotor dissolved in formic acid; purification with by-product inhibition
10/13/2005US20050227313 Polypeptide cleavage process
10/13/2005US20050227301 Cell cycle progression proteins
10/13/2005US20050227295 Constitutively activated human G protein coupled receptors
10/13/2005US20050227292 Allergenic protein complex of natural rubber latex
10/13/2005US20050227288 Synthesis and application of procainamide analogs for use in an immunoassay
10/13/2005US20050227287 Chaperones capable of binding to prion proteins and distinguishing the isoforms PrPc and PrPSc
10/13/2005US20050227283 Drosophila tumor necrosis factor class molecule ("DmTNFv2")
10/13/2005US20050227282 Human extracellular matrix-1
10/13/2005US20050227279 Methods of using torsin proteins, to prevent protein misfolding and treat protein aggregation-associated disorders
10/13/2005US20050227277 Apoptosis proteins
10/13/2005US20050227273 Protein modification and maintenance polypeptides (PMOD) for use as diagnostic and therapeutic tools in treatment of prevention of gastrointestinal, cardiovascular, autoimmune/inflammatory, cell proliferative, developmental, epithelial, neurological, and reproductive disorders
10/13/2005US20050227272 Isolated nucleic acid with polynucleotide encoding a polypeptide that interacts with I kappa B alpha probe; diagnosis or pre-diagnosis of Type 1 diabetes in an individual
10/13/2005US20050227270 Alternatively spliced isoforms of sodium channel, voltage gated, type XI, alpha (SCN11A)
10/13/2005US20050227262 polynucleotides that code for polypeptide comprising beta-ketoacyl synthase, acetyl transferase, dehydratase, methyltransferase, ketoreductase, and acyl carrier proteins; anticholesterol agents produced by Monascus
10/13/2005US20050227255 DLC-1 gene deleted in cancers
10/13/2005US20050227253 Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
10/13/2005US20050227250 Human Elk, a voltage-gated potassium channel subunit
10/13/2005US20050227249 Polymorphisms in the human MDR-1 gene and their use in diagnostic and therapeutic applications
10/13/2005US20050227243 Cell cycle progression proteins
10/13/2005US20050227238 Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74
10/13/2005US20050227237 Human neuronal attachment factor-1
10/13/2005US20050227226 Surrogate cell-based system and method for assaying the activity of hepatitis C virus NS3 protease
10/13/2005US20050227224 Infectious cDNA of an approved vaccine strain of measles virus, use for immunogenic compositions
10/13/2005US20050227220 Compositions and Methods for Evaluating and Designing Nuclear Receptor Ligands that Modulate Co-Regulator Affinity
10/13/2005US20050226934 Inclusion complexes of active compounds in acrylate (co)polymers and methods for their production
10/13/2005US20050226896 Administering to the host a live Plasmodium organism that is genetically engineered to disrupt a gene whose expression is up-regulated in liver stage parasites and whose function is not required for entry into host hepatocytes
10/13/2005US20050226895 vaccine to protect salmon against infection by Piscirickettsia salmonis, a gramnegative bacteria; salmonid rickettsial septicaemia
10/13/2005US20050226892 Methods and compositions comprising bacteriophage nanoparticles
10/13/2005US20050226891 Multiple antigenic peptides immunogenic against Streptococcus pneumonia
10/13/2005US20050226890 Tat-based vaccine compositions and methods of making and using same
10/13/2005US20050226889 Inhibition of viral infection and spread with viral and RhoA-derived peptides
10/13/2005US20050226887 Mucin antigen vaccine
10/13/2005US20050226885 Cytolysis of target cells by superantigen conjugates inducing T-cell activation
10/13/2005US20050226881 Isolated peptide which binds to HLA-Cw*07 and uses thereof
10/13/2005US20050226869 inhibiting the growth of a cell that expresses a protein of the invention; antitumor agents; identify polypeptides, cell membrane-associated, secreted or intracellular polypeptides whose expression is specifically limited to only a single (or very limited number of different) tissue type(s)
10/13/2005US20050226866 Bone morphogenic protein specific immunoglobulin for treatment of bone diseases; immunotherapy
10/13/2005US20050226864 Alteration of Fc-fusion protein serum half-lives by mutagenesis
10/13/2005US20050226862 Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders and for identifying agents therapeutic therefor
10/13/2005US20050226849 Compositions and methods of using capsid protein from Flaviviruses and Pestiviruses
10/13/2005US20050226839 Pepetide-based body surface reagents for personal care
10/13/2005US20050226813 Labelled somatostatin analogs backbone cyclized through metal complexation
10/13/2005US20050226812 Methods of therapy and diagnosis using targeting of cells that express killer cell immunoglobulin-like receptor-like proteins
10/13/2005DE60104282T2 Lösliche mutante ctla4 moleküle und deren verwendung Soluble CTLA4 mutant molecules and their use
10/13/2005DE102004015179A1 Antigen des PM-2 Antikörpers und dessen Verwendung Antigen of the PM-2 antibody and the use thereof
10/13/2005DE102004013988A1 Der Faktor RecA aus Bacillus licheniformis und recA-inaktivierte Sicherheitsstämme für die biotechnologische Produktion The factor RecA from Bacillus licheniformis and recA-inactivated safety strains for biotechnological production
10/13/2005DE102004013824A1 Nitrilhydratasen aus Rhodococcus opacus Nitrile hydratase from Rhodococcus opacus
10/13/2005CA2847454A1 Method for modification of nmda receptors through inhibition of src
10/13/2005CA2562721A1 Detection instrument with the use of polynucleotides mapped on barley chromosome
10/13/2005CA2561702A1 Methods for altering protein production rates
10/13/2005CA2561577A1 Therapeutic use of a growth factor, nsg33
10/13/2005CA2561534A1 Ion channel
10/13/2005CA2561450A1 Plants having improved growth characteristics and method for making the same
10/13/2005CA2561317A1 Bmp-3 propeptides and related methods
10/13/2005CA2560944A1 Arabinogalactan protein compositions and methods for fostering somatic embryogenic competence
10/13/2005CA2560906A1 Method for modification of nmda receptors through inhibition of src
10/13/2005CA2560849A1 Chimeric cannulae proteins, nucleic acids encoding them and methods for making and using them
10/13/2005CA2560011A1 Cospeptin, cosmedin and their uses
10/13/2005CA2559827A1 Filamentous fungal mutants with improved homologous recombination efficiency
10/13/2005CA2558742A1 Method for the recombinant expression of an n-terminal fragment of hepatocyte growth factor
10/13/2005CA2558740A1 Method for the purification of an n-terminal fragment of hepatocyte growth factor
10/13/2005CA2558615A1 Azabicyclo-octane inhibitors of iap
1 ... 1140 1141 1142 1143 1144 1145 1146 1147 1148 1149 1150 1151 1152 1153 1154 1155 1156 1157 1158 1159 1160 ... 2916